Prognostic factors and treatment outcome in childhood Hodgkin disease

Pediatric Blood and Cancer

Volumn 45, Issue 5, 2005, Pages 670-675

  Oguz, Aynur ^a   Karadeniz, Ceyda ^a   Okur, F Visal ^a   Citak, E Caglar ^a   Pinarli, F Guçlu ^a,b   Bora, Huseyin ^a   Akyurek, Nalan ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

Children; Hodgkin disease; Prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; HEMOGLOBIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMOGLOBIN DETERMINATION; HODGKIN DISEASE; HUMAN; LOW ENERGY RADIATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HEMOGLOBINS; HODGKIN DISEASE; HUMANS; LYMPHATIC METASTASIS; MALE; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 24644510659     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20487     Document Type: Article

References (34)

1. Smith RS, Chen Q, Hudson MM, et al. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy. J Clin Oncol 2003;21:2026-2033.
2. Lander T, Wiedenmann S, Wolf J. Prognostic factors in Hodgkin's lymphoma. Ann Oncol 2002; 13 67-74.
3. Donaldson SS. A discourse: The 2002 Wataru Sutow lecture Hodgkin's disease in children- perspectives and progress. Med Pediatr Oncol 2003;40:73-81.
4. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
5. Mantel N. Evaluation of survival data and two new rank-order statistics arising in its consideration. Cancer Chemother Rep 1966; 50:163-170.
6. Cavdar AO, Yavuz G, Babacan E, et al. Burkitt's lymphoma in Turkish children: Clinical, viral (EBV) and molecular studies. Leuk Lymphoma 1994;14:323-330.
7. Weiss LM, Strickler JG, Warnke RA, et al. Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am J Pathol 1987;129: 80-91.
8. Pallesen G, Hamilton-Dutoit SJ, Rowe M, et al. Expression of Epstein-Barr virus latent gene products in tumor cells of Hodgkin's disease. Lancet 1991;337:320-322.
9. Pamir A, Cavdar AO, Vontanthen R, et al. Epstein-Barr virus latent membrane protein expression and distribution of viral subtypes in Turkish Hodgkin's disease: A comparative study with non-neoplastic lymphoid hyperplasia. Med Pediar Oncol 1995;25:260 (abstr.).
10. Ertem U, Duru F, Dagdemir A, et al. Hodgkin's disease in 82 Turkish children diagnosed over a 10-year period. Pediatric Hematol Oncol 1997;14:359-366.
11. Buyukpamukçu M, Atahan L, Çalar M, et al. Hodgkin's disease in Turkish children. Clinical characteristics and treatment results of 210 patients. Pediatric Hematol Oncol 1999;16:119-129.
12. Kolygin BA. Hodgkin's disease in children: A retrospective study of the 20-year experience (1968-1987) at a single institute. Med Pediatr Oncol 1995;25:407-413.
13. Faria SL, Vassalo J, Cosset JM, et al. Childhood Hodgkin's disease in Compinas, Brazil. J Clin Oncol 1996;20:90-94.
14. Oberlin O, Leverger G, Pacqument H, et al. Low dose radiation therapy and reduced chemotherapy in chilhood Hodgkin's disease: The experience of the French Society of Pediatric Oncology. J Clin Oncol 1992;10:1602-1608.
15. Hunger SP, Link MP, Donaldson SS. ABVD/MOPP and low dose involved-field radiotherapy in pediatric Hodgkin's disease: The Stanford Experience. J Clin Oncol 1994;12:2160-2166.
16. Hudson MM, Greenwald C, Thompson E, et al. Efficacy and toxicity of multiagent chemotherapy and low-dose involved field radiotherapy in children and adolescents with Hodgkin's disease. J Clin Oncol 1993;11:100-108.
17. Matawy MS, Omar YT. Hodgkin's disease in children in Kuwait. Cancer 1986;57:2255-2259.
18. Dinshaw KA, Panda S, Advani S, et al. Pediatric Hodgkin's disease in India. J Clin Oncol 1985;3:1605-1612.
19. Hutchinson RJ, Fryer CJH, Davis PC, et al. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: Results of the Children's Cancer Group phase III trial. J Clin Oncol 1998;16:897-906.
20. Vecchi V, Pileri S, Burnelli R, et al. Treatment of pediatric Hodgkin's disease tailored to stage, mediastinal mass, and age: An Italian (AIEOP) multicenter study on 215 patients. Cancer 1993; 72:2049-2056.
21. Weiner MA, Leventhal BG, Marcus R, et al. Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: A Pediatric Oncology Group study. J Clin Oncol 1991;9:1591-1598.
22. Schellong G, Potter R, Bramswig J, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: The German-Austrian multicenter trial DAL-HD-90 - The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999;17:3736-3744.
23. Landman-Parker J, Pacquement H, Leblanc T, et al. Localized childhood Hodgkin's disease: Response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy - Results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 2000;18:1500-1507.
24. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998;339:1506-1514.
25. Specht L, Lauritzen AF, Nordentoft AM, et al. Tumor cell concentration and tumor burden in relation to histopathologic subtype and other prognostic factors in early stage Hodgkin's disease. The Danish National Hodgkin Study Group. Cancer 1990;65:2594-2601.
26. Tubiana M, Henry-Amar M, Werf-Messing B, et al. A multivariate analysis of prognostic factors in early stage Hodgkin's disease. Int J Radiat Oncol Biol Phys 1985;11:23-30.
27. Tubiana M, Henry-Amar M, Hayat M, et al. Prognostic significance of number of involved areas in early stages of Hodgkin's disease. Cancer 1984;54:885-894.
28. Sarris AH, Kliche KO, Nadali G. Biologic factors in Hodgkin's disease: A window into prognosis and a guide for investigational therapy. Leuk Lymphoma 2001;42:10.
29. Gobbi PG, Comelli M, Grignani GE, et al. Estimate of expected survival at diagnosis in Hogkin's disease: A means of weighting prognostic factors and a tool for treatment choice and clinical research. A report from the International Database on Hodgkin's Disease (IDHD). Haematologica 1994;79:241-255.
30. Bradley AJ, Carrington BM, Lawrance JAL, et al. Assessment and significance of mediastinal bulk in Hodgkin's disease: Comparison between computed tomography and chest radiography. J Clin Oncol 1999;17:2493-2498.
31. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7: 1630-1636.
32. Rosenberg SA, Kapan HS. The evaluation and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984. Int J Radat Oncol Biol Phys 1985;11:5-22.
33. Specht L. Prognostic factors in Hodgkin's disease. Cancer Treat Rev 1991;18:21-53.
34. Hasenclever D. The disappearance of prognostic factors in Hodgkin's disease. Ann Oncol 2002;13:75-78.